Archive for May, 2012

The Bon-Ton Stores, Inc. (BONT) Announces May Sales

~Comparable Store Sales Increased 1.5% ~

The Bon-Ton Stores, Inc. (NASDAQ: BONT) today announced comparable store sales in the four weeks ended May 26, 2012 increased 1.5%. Total sales increased 1.2% to $183.1 million in the current year compared with $181.0 million in the prior year period.

Year-to-date comparable store sales decreased 0.7%. Year-to-date total sales decreased 0.8% to $823.9 million compared with $830.9 million in the same period last year.

Brendan Hoffman, President and Chief Executive Officer, commented, “We are pleased with our May sales performance, as compelling new offerings and refinements in our marketing efforts yielded positive results. Our eCommerce business continued to post double-digit sales increases, and we are very encouraged that our aggressive pursuit of traditional product resulted in an improved performance in ladies’ ready-to-wear, particularly moderate sportswear, as customers responded favorably to new receipts. Month-end comparable store inventories increased approximately 3% over the prior year, reflecting increased investment to support our sales initiatives. We look to drive sustained improved performance as we continue to implement our merchandising and marketing strategies.”

Keith Plowman, Executive Vice President and Chief Financial Officer, stated, “Our excess borrowing capacity under our revolving credit facility was approximately $423 million at the end of May.”

The Bon-Ton Stores, Inc., with corporate headquarters in York, Pennsylvania and Milwaukee, Wisconsin, operates 272 department stores, which includes 11 furniture galleries, in 23 states in the Northeast, Midwest and upper Great Plains under the Bon-Ton, Bergner’s, Boston Store, Carson Pirie Scott, Elder-Beerman, Herberger’s and Younkers nameplates and, in the Detroit, Michigan area, under the Parisian nameplate. The department stores offer a broad assortment of national and private brand fashion apparel and accessories for women, men and children, as well as cosmetics and home furnishings. For further information, please visit the investor relations section of the Company’s website at http://investors.bonton.com.

Certain information included in this press release contains statements that are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, which may be identified by words such as “may,” “could,” “will,” “plan,” “expect,” “anticipate,” “estimate,” “project,” “intend” or other similar expressions, involve important risks and uncertainties that could significantly affect results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by or on behalf of the Company. Factors that could cause such differences include, but are not limited to, risks related to retail businesses generally; a significant and prolonged deterioration of general economic conditions which could negatively impact the Company, including the potential write-down of the current valuation of intangible assets and deferred taxes; changes in the terms of the Company’s proprietary credit card program; potential increase in pension obligations; consumer spending patterns, debt levels, and the availability and cost of consumer credit; additional competition from existing and new competitors; inflation; deflation; changes in the costs of fuel and other energy and transportation costs; weather conditions that could negatively impact sales; uncertainties associated with expanding or remodeling existing stores; the ability to attract and retain qualified management; the dependence upon relationships with vendors and their factors; a data security breach or system failure; the ability to reduce or control SG&A expenses, including initiatives to reduce expenses and improve efficiency; operational disruptions; unsuccessful marketing initiatives; the failure to successfully implement our key strategies, including initiatives to improve our merchandising, marketing and operations; adverse outcomes in litigation; the incurrence of unplanned capital expenditures; the ability to obtain financing for working capital, capital expenditures and general corporate purpose; the impact of new regulatory requirements including the Credit Card Accountability Responsibility and Disclosure Act of 2009 and the Health Care Reform Act; the inability or limitations on the Company’s ability to favorably adjust the valuation allowance on deferred tax assets; and the financial condition of mall operators. Additional factors that could cause the Company’s actual results to differ from those contained in these forward-looking statements are discussed in greater detail under Item 1A of the Company’s Form 10-K filed with the Securities and Exchange Commission.

Thursday, May 31st, 2012 Uncategorized Comments Off on The Bon-Ton Stores, Inc. (BONT) Announces May Sales

ImmunoCellular (IMUC) to Present Long-term Oncology Survival Data

ImmunoCellular Therapeutics to Present Long-term Survival Data from Clinical Study of ICT-107 in Glioblastoma Multiforme at American Society of Clinical Oncology Meeting

ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC), announced today it will present new data from the previously completed Phase I clinical trial of ICT-107, the Company’s lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL. The abstract, titled “Correlation of survival with tumor antigen expression in patients with newly diagnosed glioblastoma receiving a multi-epitope pulsed dendritic cell vaccine” (Abstract #2087), has been accepted for presentation on June 2, 2012 from 1:15 PM to 5:15 PM, during the Central Nervous System Tumors General Poster Session. The data will show that there is downregulation of both the tumor associated antigens that ICT-107 is targeting as well as CD-133, a cancer stem cell (CSC) marker, in some of the patients. These observations suggest that targeting antigens highly expressed by CSCs is a promising strategy for treating patients with GBM.

Updated data from the 16 patients in the Phase I trial shows that patients treated with ICT-107 reported overall survival (OS) of 50% after four years and 38% of the trial patients are progression free (PFS) for 48-66 months. This compares very favorably to historic mean OS of 12.1% after four years and 5.6 % PFS after 48 months with standard of care alone.

While not all 16 of the patients in the Phase I trial have crossed the five-year time point, three of the patients are disease-free for five years. Cancer stem cell population measured by CD-133 in patients who went through a second surgery has gone down by a multiple of 3-5 times. Usually the CSC population goes up 3-5 times with the standard of care treatment alone, which appears to validate ICT-107’s mechanism of action. The positive trend between the expression of gp-100, MAGE-1, AIM-2 and Her-2 and PFS appears to indicate that those cells are more susceptible to respond to the vaccination. In addition, several of these antigens were downregulated over time, further validating the mechanism of action of ICT-107. This new data follows previously announced two-year results showing an OS rate of 80% and a PFS rate of 44%, which compare very favorably to historic median survival rates with standard of care alone.

In ImmunoCellular’s follow-on Phase II trial of ICT-107, there are 213 patients enrolled to date, of which 100 patients have been either randomized (or treated with the product) or are waiting to complete radiation therapy prior to treatment. The Company recently announced that its Phase II trial is now on-going at 25 sites, with patients enrolled in leading medical centers such as Mass General Cancer Center and the Dana Farber Cancer Institute. ImmunoCellular plans to continue enrollment for a short time to ensure enough patients will be available for the data analysis. The trial, as originally designed, was to enroll over 200 patients to treat at least 102 patients with HLA-A1/A2 immunological subtypes.

“The continued impressive survival data we have seen to date and the timely enrollment in our ongoing Phase II trial, further build our confidence that targeting CSCs may provide a breakthrough in the treatment of GBM,” said Manish Singh, Ph.D., President and CEO of ImmunoCellular. “As we complete enrollment of our Phase II trial, we look forward to obtaining patient data.”

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company has commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. To learn more about the Company, please visit www.imuc.com.

Forward-Looking Statements for ImmunoCellular Therapeutics

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that prior safety and efficacy results for ICT-107 will not be confirmed in current or any subsequent trials in statistically significant larger patient populations; and the risks associated with adhering to clinical timeframes. Additional risks and uncertainties are described in IMUC’s most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Thursday, May 31st, 2012 Uncategorized Comments Off on ImmunoCellular (IMUC) to Present Long-term Oncology Survival Data

Penson (PNSN) and PEAK6 Announce Formation of Apex Clearing

Creates Well-Capitalized Entity with New Leadership to Provide Customer Stability

Penson Worldwide, Inc. (NASDAQ: PNSN), and PEAK6 Investments, LP, today announced the formation of Apex Clearing Corporation. Under the terms of the agreement, Apex Clearing has agreed to acquire the correspondent and customer accounts and contracts of the securities division of Penson’s U.S. broker–dealer subsidiary Penson Financial Services, Inc. (PFSI) which covers approximately 230 U.S. based securities correspondents and one million customer accounts. The agreement does not include Penson’s Futures or Canadian Operations. Apex Clearing is expected to begin operations in the coming days following the completion of certain closing conditions and receipt of required regulatory approval from the U.S. Securities and Exchange Commission and FINRA.

The formation of Apex Clearing brings much needed stability to customers and the capital markets. Apex Clearing is an independent, privately held clearing services firm with the capital position and enhanced leadership, technology, and risk management expertise necessary to provide ongoing, sustained support of its customers’ clearing needs. The completion of the transaction is expected to allow customers to continue to conduct their brokerage business as usual.

PEAK6 will provide capital, the management team, day-to-day operational oversight, and risk management discipline necessary to run the business. Danny Rosenthal, a senior partner at PEAK6, will be Chief Executive Officer of Apex Clearing. PFSI will initially provide transitional services and retain a majority economic interest in Apex Clearing. Broadridge Financial Solutions and Apex Clearing are putting a new agreement in place for Broadridge to provide the securities processing technology platform and back office services for Apex Clearing which Broadridge currently provides to support Penson’s correspondents.

“This transaction resolves an urgent need in the marketplace today to maintain stability and continuity for Apex Clearing’s customers,” said Brad Goldberg, President of PEAK6. “PEAK6 brings a focus on strong management, sophisticated technology platforms, and a disciplined approach to risk which will provide stability for customers.”

Bryce Engel, President of Penson Worldwide, added, “We believe this transaction represents the best solution for our U.S. securities correspondents, their customers, and related counterparties, as well as for our other stakeholders. From a position of strength, Apex Clearing will be able to convert new correspondents and grow the business.”

“We are pleased to support the formation of Apex Clearing,” said Richard J. Daly, Chief Executive Officer of Broadridge Financial Solutions. “Apex Clearing is the most recent example of how leveraging our flexible technology solutions provides Broadridge’s clients with seamless transition options and an ability to focus on growing their businesses. Participating in the ongoing stability of our capital markets and providing future growth opportunities for our shareholders directly aligns with Broadridge’s values and mission.”

Additional details of the transaction will be provided in subsequent Penson and Broadridge filings with the U.S. Securities and Exchange Commission.

About PEAK6 INVESTMENTS LP: www.peak6.com

PEAK6 Investments, L.P. is a leading financial institution with headquarters in Chicago, and offices in Seattle, New York and San Francisco. Established in 1997, PEAK6 has a demonstrated track record of success in proprietary trading, retail brokerage, technology innovation, and risk management. PEAK6 focuses on innovation, execution prowess and nurtures a highly dynamic, entrepreneurial culture.

About Penson Worldwide: www.penson.com

The Penson Worldwide group of companies provides execution, clearing, custody, settlement and technology infrastructure products and services to financial services firms and others servicing the global financial services industry. The Penson Worldwide group of companies includes Penson Financial Services, Inc., Penson Financial Services Canada Inc., and Nexa Technologies, Inc., among other companies. Headquartered in Dallas, Texas, Penson has served the clearing needs of the global financial services industry since 1995.

Penson Forward-Looking Statements: Statements contained in this news release that are not based on current or historical fact are forward-looking in nature. Such forward-looking statements are based on current plans, estimates and expectations. Forward-looking statements are based on known and unknown risks, assumptions, uncertainties and other factors. Actual results, performance, or achievements may differ materially from any future results, performance, or achievements expressed or implied by such forward-looking statements. Penson undertakes no obligation to publicly update or revise any forward-looking statement.

Thursday, May 31st, 2012 Uncategorized Comments Off on Penson (PNSN) and PEAK6 Announce Formation of Apex Clearing

Prima BioMed (PBMD) to Host Shareholder Briefing

SYDNEY, AUSTRALIA — (Marketwire) — 05/31/12 — Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (Prima, the Company) advises that it will hold a shareholder briefing with the Company’s CEO designate Matthew Lehman, current CEO Martin Rogers, Chairman Lucy Turnbull, and Deputy Chairman Albert Wong in Sydney, Australia, on Friday, 15 June 2012.

The briefing will provide an opportunity for Mr. Lehman to meet shareholders and deliver an update on the Company’s activities.

Mr. Lehman, who is currently Prima’s Chief Operating Officer, will become the Company’s CEO effective 1 September 2012 (see ASX announcement of 24 May).

Details of the shareholder briefing:

Date:
Friday, 15 June 2012

Time:
9:30am to 11:00am AEST (local time)

Venue:
Radisson Blu Hotel Sydney
27 O’Connell St Sydney (Marble Room 2 and 3)

Shareholders outside Sydney will be able to access the briefing via a webcast and dial-in facility. Webcast and dial-in details will be provided on the Prima BioMed and ASX websites prior to the meeting.

Shareholders, and other interested parties, are kindly requested to RSVP to enquiries@primabiomed.com.au prior to the event to assist in planning the meeting. Shareholders are also encouraged to submit questions or comments via email prior to the meeting.

Prima has updated the Company Calendar section of its website to include this shareholder briefing and other relevant upcoming public presentations.

About Prima BioMed

Prima BioMed is a global biotechnology company headquartered in Australia. As a leader in personalised bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximise value to shareholders. Prima’s lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer.

For further information please contact:

Australia Investor/Media:
Mr. James Moses
Mandate Corporate
+61 (0) 420 991 574
Email Contact

USA Investor/Media:
Ms. Kathy Galante
Burns McClellan Inc.
+1 (212) 213-0006
Email Contact

Europe Investor/Media:
Mr. Axel Mühlhaus
edicto GmbH
+49 (0) 69 905505-52

Thursday, May 31st, 2012 Uncategorized Comments Off on Prima BioMed (PBMD) to Host Shareholder Briefing

MicroVision (MVIS) Receives Purchase Orders in Excess of $4M

MicroVision, Inc. (NASDAQ:MVIS), a leader in innovative ultra-miniature projection display technology, today announced that it has received purchase orders from Pioneer Corporation valued in excess of $4 million. The purchase orders cover key components, including MEMS and electronics, which are part of the company’s patented next generation HD PicoP® display technology based on direct green lasers (PicoP Gen2) that Pioneer is integrating into its Cyber Navi car navigation system.

Pioneer is MicroVision’s first customer under its Image by PicoP ingredient brand business model whereby it sells components and receives license fees and royalties for its patented PicoP display technology. Pioneer’s Cyber Navi head-up display (HUD) is the first commercial product based on MicroVision’s PicoP Gen2 display technology.

MicroVision has already begun shipping components to Pioneer for its aftermarket HUD product that is expected to be available in Japan in July. The Cyber Navi is the world’s first HUD to project augmented reality information in front of the windscreen and the world’s first onboard HUD to use lasers. The product was designed to offer drivers a new way to experiencing data on the road.

Pioneer will combine the MEMS and electronics it receives from MicroVision with red, blue and direct green lasers from Pioneer’s laser suppliers to create optical engines based on MicroVision’s patented PicoP reference design. The PicoP display technology embedded in the HUD delivers bright, clear, full color images viewable in daylight in a small form factor with low power requirements.

About MicroVision

MicroVision provides the PicoP® display technology platform designed to enable next-generation display and imaging products for consumer devices, vehicle displays and wearable displays. The company’s PicoP projection display technology uses highly efficient laser light sources which can create vivid images with high contrast and brightness.

MicroVision is an independently recognized leader in the development of intellectual property. MicroVision has been recognized by IEEE as a top 20 IP portfolio among all global electronics companies, and the top U.S. Company in the rankings. MicroVision’s intellectual property portfolio has also been recognized by the Patent Board, in association with the Wall Street Journal as a top 50 IP portfolio among all global industrial companies. The Patent Board has developed more than 50 indicators that track global patent activity relating to companies’ innovation, technology, and science strengths. MicroVision’s intellectual property portfolio is further recognized by having been added to the Ocean Tomo 300 Patent Index. The Index is priced and published by the NYSE Euronext (NYSE: OTPAT). The index is objectively based on the value of intellectual property compared to competitors.

For more information, visit us on:

Website: www.microvision.com
Blog: www.microvision.com/displayground
Twitter: www.twitter.com/microvision
Facebook: www.facebook.com/MicrovisionInc
YouTube: www.youtube.com/mvisvideo

Forward-Looking Statements

Certain statements contained in this release, including those relating to future products and operating results, and those using words such as “designed to” and “will” and words with similar meanings are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the forward-looking statements include the following: our ability to raise additional capital when needed; our or our customers’ failure to perform under purchase orders; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market our products; potential product liability claims; and other risk factors identified from time to time in the company’s SEC reports, including the company’s Annual Report on Form 10-K filed with the SEC. Except as expressly required by federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.

Thursday, May 31st, 2012 Uncategorized Comments Off on MicroVision (MVIS) Receives Purchase Orders in Excess of $4M

Synthesis (SYMX) Initiates Pre-Commissioning on Syngas Plant Startup at Yima Joint Venture

HOUSTON, May 30, 2012 /PRNewswire/ — Synthesis Energy Systems, Inc. (Nasdaq: SYMX) (“SES”) announced today that it has deployed a pre-commissioning team to the Yima Joint Venture project in Henan Province, China. This team will inspect the SES technology, equipment and related gasification systems at the Yima Joint Venture project over the next several weeks to ensure the installation is ready to operate as designed once construction is completed. The first syngas production from the project is expected this summer.

The pre-commissioning team is comprised of SES China technology and engineering team members as well as several operations and maintenance personnel from the Company’s Zao Zhuang Joint Venture project in Zao Zhuang City, Shandong Province, China. Once the pre-commissioning and construction periods are complete, the project will advance into the commissioning phase during which the team will complete operating systems functionality tests ahead of the project startup.

Colin Tam, Managing Director of SES China, stated, “The successful startup of the Yima Joint Venture Project is an important milestone for our company not only in China but also globally. We have recently mobilized our pre-commissioning team to assist our partner Yima in their planned startup this summer.  We look forward to working diligently with our partner to complete the project on schedule and within budget.”

Robert Rigdon, SES President and CEO, commented, “I am pleased that our project is advancing well. We believe this large scale chemicals facility will provide the Yima Joint Venture with meaningful revenues and earnings once in full commercial operation, and that SES’ 25% ownership share in the Yima Joint Venture will enable us to grow more rapidly in China. This large-scale project is very important to SES as many of our customers in China and globally desire to move rapidly to implement our technology at large scale to benefit from our very low cost coal capability.”

About Synthesis Energy Systems, Inc.

SES provides technology, equipment and engineering services for the conversion of low rank, low cost coal and biomass feedstocks into energy and chemical products. Its strategy is to create value through providing technology and equipment in regions where low rank coals and biomass feedstocks can be profitably converted into high value products through its proprietary U-GAS® fluidized bed gasification technology, which SES licenses from the Gas Technology Institute. U-GAS® gasifies coal cost effectively, without many of the harmful emissions normally associated with coal combustion plants. The primary advantages of U-GAS® relative to other gasification technologies are (a) greater fuel flexibility provided by the ability of SES to use all ranks of coal (including low rank, high ash and high moisture coals, which are significantly cheaper than higher grade coals), many coal waste products and biomass feed stocks; and (b) the ability of SES to operate efficiently on a smaller scale, which enables the construction of plants more quickly, at a lower capital cost, and, in many cases, in closer proximity to coal sources. SES currently has offices in Houston, Texas, and Shanghai, China. For more information on SES and SRS, visit www.synthesisenergy.com or call (713) 579-0600.

SES Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are the early stage of development of SES, its estimate of the sufficiency of existing capital sources, its ability to successfully develop its licensing business, its ability to raise additional capital to fund cash requirements for future investments and operations including its China platform initiative, its ability to reduce operating costs, the limited history and viability of its technology, commodity prices and the availability and terms of financing opportunities, its results of operations in foreign countries, its ability to diversify, its ability to complete the restructuring of the ZZ Joint Venture, its ability to obtain the necessary approvals and permits for its future projects, the estimated timetables for achieving mechanical completion and commencing commercial operations for the Yima project as well as the ability of the Yima project to produce revenues and earnings, the sufficiency of internal controls and procedures and the ability of SES to effect the ZJX/China Energy transaction, grow its business and generate revenues and earnings as a result of its proposed China and India platform initiatives, as well as its joint venture with Midas Resource Partners. Although SES believes that in making such forward-looking statements its expectations are based upon reasonable assumptions, such statements may be influenced by factors that could cause actual outcomes and results to be materially different from those projected. SES cannot assure you that the assumptions upon which these statements are based will prove to have been correct.

Important Notice from SES

In connection with the proposed ZJX/China Energy transaction, SES has filed a preliminary proxy statement, and intends to file a definitive proxy statement, with the SEC and intends to mail the definitive proxy statement to the stockholders of SES. SES and its directors and officers may be deemed to be participants in the solicitation of proxies from the stockholders of SES in connection with the transaction. Information about the transaction is set forth in the preliminary proxy statement filed, and will be set forth in the definitive proxy statement to be filed by SES with the SEC.

You may obtain the preliminary statement and, when available, the definitive proxy statement, for free by visiting EDGAR on the SEC website at www.sec.gov. Investors should read the definitive proxy statement carefully before making any voting or investment decision because that document will contain important information.

Wednesday, May 30th, 2012 Uncategorized Comments Off on Synthesis (SYMX) Initiates Pre-Commissioning on Syngas Plant Startup at Yima Joint Venture

Zogenix (ZGNX) Submits IND for Second DosePro(R) Candidate Relday(TM)

Potential First Needle-Free Subcutaneous Treatment Option in $2 Billion Long-Acting Injectable Antipsychotic Market

SAN DIEGO, May 30, 2012 (GLOBE NEWSWIRE) — Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food & Drug Administration (FDA) for Relday™, which is a combination of Zogenix’s DosePro® needle-free, subcutaneous drug delivery system plus a proprietary, subcutaneous once-monthly formulation of risperidone for treating schizophrenia. In July 2011, Zogenix licensed from DURECT (Nasdaq:DRRX) exclusive global rights to develop and commercialize this proprietary formulation which utilizes DURECT’s SABER® depot technology. Initial clinical trials are currently planned to begin in the second half of the year, with results expected by year-end.

Risperidone is one of the most widely prescribed medications used to treat the symptoms of schizophrenia in adults and teenagers 13 years of age and older. The global long-acting injectable antipsychotic market was approximately $2 billion in 2011, with currently approved products using a 21-gauge or larger needle for intramuscular injections. The leading product in the category requires twice-a-month dosing and drug reconstitution prior to use. The combined market for oral and injectable antipsychotic products was estimated at more than $16 billion in 2010.

If approved, Relday will be the first subcutaneous, needle-free antipsychotic product that allows for once-monthly dosing. Zogenix believes that Relday will offer an improved pharmacokinetic profile, significant reduction in injection volume and a simplified dosing regimen due to DURECT’s SABER controlled-release formulation technology in combination with Zogenix’s DosePro needle-free subcutaneous drug delivery system.

Roger L. Hawley, chief executive officer of Zogenix, said, “We are encouraged by Relday’s potential of improving patient compliance due to the safety and convenience provided by DosePro’s needle-free delivery system combined with a long-acting formulation of an established antipsychotic. Our market research indicates that psychiatrists prefer a subcutaneous, needle-free, once-monthly treatment option over products that are currently available.”

Hawley continued, “We anticipate having study results toward the end of the year which could position us to begin discussions regarding a rest-of-world development and commercialization partner. Should Relday receive FDA approval, it will also further validate the potential use of DosePro to enable the delivery of viscous drug formulations such as biologics.”

About DosePro®

The DosePro system is a first-in-class, easy-to-use drug delivery system that includes a pre-filled, single dose of liquid drug, and is administered subcutaneously, without a needle. The platform is currently used by Zogenix’s first commercial product, SUMAVEL® DosePro®, and its investigational candidate, Relday. The Company believes that DosePro offers several benefits to patients compared to other subcutaneous delivery methods, and that it has the potential to become a preferred delivery option for patients and physicians. These benefits include less anxiety or fear due to the lack of a needle, easier disposal without the need for a sharps container, no risk of needle stick injury or contamination, an easy-to-use three step process, no need to fill or manipulate the device, reliable performance, discreet use and portability. In several clinical trials and market research studies, DosePro has been shown to be preferred by patients over conventional needle-based systems.

Zogenix has entered into an agreement with Battelle, an independent research and development organization, to co-market the DosePro technology to potential pharmaceutical and government clients with the objective of licensing the system for use with innovative therapeutics that would be enabled or enhanced by DosePro’s unique needle-free delivery system. Compared to other delivery technologies, DosePro has the potential to solve the significant challenges of delivering viscous drug formulations, such as high concentration biologics, which cannot be delivered with traditional needle-based injection. The DosePro drug delivery technology is covered by more than 46 internationally issued patents extending through 2026.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix’s first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix’s lead investigational product candidate, Zohydro™ (hydrocodone bitartrate) is a novel, oral, single-entity (without acetaminophen) extended-release formulation of various strengths of hydrocodone intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix submitted an NDA to the FDA for Zohydro in May 2012. Zogenix’s second DosePro investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia.

For additional information, please visit www.zogenix.com.

Forward Looking Statements

Zogenix cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “intends,” “potential,” “suggests,” “assuming” and similar expressions are intended to identify forward-looking statements. These statements are based on the company’s current beliefs and expectations. These forward-looking statements include statements regarding development of a commercially successful product, the initiation of clinical trials and results from such trials and the timing thereof, the ability of such product to address the global anti-psychotic market, the ability to develop a once-monthly injectable product with improved pharmacokinetics and significant reduction in injection volume, ability to achieve first-in-class status, partnering opportunities for Relday outside the United States, and leveraging the DosePro technology. The inclusion of forward-looking statements should not be regarded as a representation by Zogenix that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in Zogenix’s business, including, without limitation: the uncertainties associated with the clinical development and regulatory approval of product candidates such as Relday, including the timing and outcome of the FDA’s review of the IND for Relday; difficulties in identifying, negotiating, executing and carrying out strategic transactions relating to Relday; the market potential for anti-psychotics, and Zogenix’s ability to compete within that market; ability to obtain and the validity and duration of patent protection and other intellectual property rights for Relday; and other risks described in the company’s prior press releases and filings with the Securities and Exchange Commission.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Zogenix undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

SUMAVEL®, DosePro®, ReldayTM and ZohydroTM are trademarks of Zogenix, Inc.

SABER® is a trademark of DURECT Corporation.

CONTACT: Investor Contact
         Zack Kubow| The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         Media Contact
         The Ruth Group
         Victoria Aguiar
         646.536.7013 | vaguiar@theruthgroup.com
Wednesday, May 30th, 2012 Uncategorized Comments Off on Zogenix (ZGNX) Submits IND for Second DosePro(R) Candidate Relday(TM)

Thomas Properties Group, Inc. (TPGI) Private Placement of $50M in Common Stock

Thomas Properties Group, Inc. (NASDAQ:TPGI) announced today that it has entered into a definitive purchase agreement with certain institutional accredited investors affiliated with Madison International Realty with respect to the private placement of 8,695,693 shares of its common stock at a purchase price of $5.75, per share, for expected gross proceeds of approximately $50 million before payment of estimated transaction expenses. The closing of this private placement is expected to occur on or about June 12, 2012, subject to customary closing conditions. On May 29, 2012, the closing price of the company’s common stock on the NASDAQ Global Market was $4.05 per share.

In connection with the purchase agreement, the investors also entered into a Stockholders’ Agreement with TPGI and James A. Thomas, our Chairman and Chief Executive Officer, and certain stockholders affiliated with Mr. Thomas, providing for certain lock-up, standstill, preemptive rights and voting agreements by TPGI, the investors, Mr. Thomas and the other affiliated stockholders. The investors will have the right to name one person to become a director of TPGI at the next regular meeting of the Board of Directors. In addition, TPGI entered into a registration rights agreement with the investors pursuant to which it has granted certain rights for the filing of registration statements under the Securities Act of 1933, as amended (the “Securities Act”), with respect to the registration for resale of the shares of common stock issued in the private placement, certain other shares of common stock currently owned by the investors and securities acquired pursuant to the exercise of preemptive rights.

No underwriting discounts or commissions will be paid by TPGI with respect to the sale of the shares, but TPGI has agreed to reimburse the investors for certain transaction expenses. Net proceeds of the private placement will be used for general corporate purposes, including potential acquisitions.

This private placement of securities was made only to select institutional accredited investors in accordance with Section 4(2) under the Securities Act and the rules and regulations promulgated thereunder. The securities offered in this private placement have not been registered under the Securities Act or the securities laws of any other jurisdiction, and may not be offered or sold in the United States or to any U.S. persons absent registration with the Securities and Exchange Commission (the “SEC”) and any applicable state securities laws, or an applicable exemption therefrom.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sales of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Madison International Realty

Madison International Realty (www.madisonint.com) is a leading liquidity provider to real estate investors and companies worldwide. Madison provides strategic equity capital for recapitalizations, partner buyouts and balance sheet restructurings through the acquisition of joint venture, limited partner and co-investment interests as principals and invests in equity securities of undervalued public companies. With approximately $1 billion in assets under management, Madison invests in direct secondary transactions and directly in companies focused on Class A properties and portfolios in the U.S., U.K., and Western Europe. Founded in 1996, Madison has offices in New York, London and Frankfurt, Germany.

About Thomas Properties Group

Thomas Properties Group, Inc., based in Los Angeles, is a full-service real estate company that owns, acquires, develops and manages primarily office, as well as mixed-use and residential properties on a nationwide basis. The company’s primary areas of focus are the acquisition and ownership of premier properties, both on a consolidated basis and through its strategic joint ventures, property development and redevelopment, and property management and leasing activities. For more information about Thomas Properties Group, Inc., please visit www.tpgre.com.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, statements made in this press release, including those relating to the private placement and the use of proceeds therefrom, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the company’s control, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. For a discussion of some of the factors that may cause our results to differ from management’s expectations, see the information under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Factors That May Influence Future Results of Operations” in our Form 10-K for the year ended December 31, 2011, and our Quarterly Reports on Form 10-Q and other filings with the SEC. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Wednesday, May 30th, 2012 Uncategorized Comments Off on Thomas Properties Group, Inc. (TPGI) Private Placement of $50M in Common Stock

NCI (NCIT) Awarded National Institute of Health’s CIO-SP3 GWAC with $20B Ceiling

NCI, Inc. (NASDAQ:NCIT), a leading provider of information technology (IT) and professional services and solutions to U.S. Federal Government agencies, announced today that it was an awardee on the $20B ceiling Chief Information Officers-Solutions and Partners (CIO-SP3) Government Wide Acquisition Contract (GWAC). The National Institutes of Health (NIH) Information Technology Acquisition and Assessment Center (NITAAC) posted the awards. The broad-based IT contract focuses on health and biomedical-related IT services, with a period of performance is 10 years, and representing new business for NCI.

Under the contract, NCI is eligible to compete for task orders in ten functional areas including Healthcare IT Services, Chief Information Officer (CIO) Support, Imaging, Outsourcing, IT Operations and Maintenance, Integration Services, Government Outsourcing, Critical Infrastructure Protection and Information Assurance, Digital Government, Enterprise Management Systems, and Software Development. CIO-SP3 is a successor to the highly successful CIO-SP2i and the Image World2 New Dimensions GWACs.

“NCI is delighted to have been awarded the CIO-SP3 contract. This award enables NCI and its large and small business teammates to provide a wide array of innovative solutions in health IT and other functional areas to NIH and other federal agencies. The award further expands our portfolio of major prime GWAC, IDIQ and other multiple-award vehicles, particularly in the area of federal health IT,” said NCI’s President, Brian Clark.

About NCI, Inc.:

NCI is a leading provider of IT and professional services and solutions to U.S. Federal Government agencies. NCI’s award-winning expertise encompasses areas critical to its customers’ mission objectives, including enterprise systems management; network engineering; cybersecurity and information assurance; software development and systems engineering; program management, acquisition, and lifecycle support; engineering and logistics; health IT and informatics; and training and simulation. The company is a member of the Russell 2000 and S&P Small Cap 600 indexes. Headquartered in Reston, VA, NCI has approximately 2,300 employees at more than 100 locations worldwide. For more information, visit our website at www.nciinc.com, or email mcrystal@nciinc.com.

Forward-Looking Statement: Statements and assumptions made in this press release, which do not address historical facts, constitute “forward-looking” statements that NCI, Inc. believes to be within the definition in the Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties, many of which are outside of our control. Such forward-looking statements are subject to factors that could cause actual results to differ materially from those anticipated results. These factors include but are not limited to: the failure of the Government to allot funds to NCI to complete performance of the contract; the risk of contract performance; government contract procurement (such as bid protest) and termination risks; competitive factors such as pricing pressures and/or competition to hire and retain employees; and material changes in laws or regulations applicable to the company’s businesses. For a discussion of these and other risks and uncertainties, please refer to the section titled “Risk Factors” in the NCI, Inc. Form 10-K filed with the Securities and Exchange Commission for the period ended December 31, 2011. The forward-looking statements included in this news release are only made as of the date of this news release and NCI, Inc. undertakes no obligation to publicly update any of the forward-looking statements made herein, whether as a result of new information, subsequent events or circumstances, changes in expectations or otherwise.

Wednesday, May 30th, 2012 Uncategorized Comments Off on NCI (NCIT) Awarded National Institute of Health’s CIO-SP3 GWAC with $20B Ceiling

Trovagene, Inc. (TROV) 1.15M Units, NASDAQ Listing, Effectiveness of Reverse Stock Split

SAN DIEGO, May 30, 2012 /PRNewswire/ — Trovagene, Inc. (Nasdaq: TROV),a developer of trans-renal molecular diagnostics, announced the pricing of an underwritten public offering of 1,150,000 units at an offering price of $8.00 per unit, with each unit consisting of two shares of common stock and one warrant to purchase one share of common stock. The units will begin trading on The NASDAQ Capital Market on May 30, 2012 under the symbol “TROVU.” The common stock and warrants will not be separately transferable until the earlier of (i) the exercise in full of the underwriters’ overallotment option or (ii) 45 days from the date of the prospectus. Each warrant will have an exercise price of $5.32 per share, will be exercisable upon separation of the units and will expire five years from the closing of the offering. When separately transferable, the warrants will trade on The NASDAQ Capital Market under the symbol “TROVW.” The gross proceeds to Trovagene from this offering are expected to be $9.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on June 4, 2012, subject to customary closing conditions. Trovagene has also granted the underwriters a 45-day option to purchase up to an additional 172,500 units to cover over-allotments, if any. All of the units in the offering are to be sold by Trovagene.

Trovagene intends to use the net proceeds from this offering to fund its research and development activities, and for working capital and other general corporate purposes and possibly acquisitions of other companies, products or technologies, though no such acquisitions are currently contemplated.

Trovagene also announced that, effective as of May 30, 2012, its common stock will begin trading on The NASDAQ Capital Market under the symbol “TROV.”  In connection with its listing on The NASDAQ Capital Market, Trovagene’s common stock will cease trading on the OTC QB.  Furthermore, in connection with this offering, Trovagene has effected a 1-for-6 reverse stock split of its common stock which is effective for trading purposes as of May 30, 2012.

Aegis Capital Corp. is acting as the sole book-running manager.

Summer Street Research Partners and Brean Murray, Carret & Co., LLC are acting as co-managers.  A registration statement on Form S-1 relating to the units was filed with the Securities and Exchange Commission and is effective.  A preliminary prospectus relating to the offering has been filed with the SEC and is available on the SEC’s web site at http://www.sec.gov. Copies of the final prospectus relating to the offering, when available, may be obtained from the offices of Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 11th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com, or from the above-mentioned SEC website.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.

Trovagene has a dominant patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in CLL (chronic lymphocytic leukemia) patients.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend,” among others. These forward-looking statements are based on Trovagene’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Trovagene’s Form 10-K for the year ended December 31, 2011 and other periodic reports filed with the Securities and Exchange Commission.

Contact:

Company:
Trovagene, Inc.
Stephen Zaniboni
Chief Financial Officer
+1 (858) 496-7466
szaniboni@trovagene.com
http://www.trovagene.com

Wednesday, May 30th, 2012 Uncategorized Comments Off on Trovagene, Inc. (TROV) 1.15M Units, NASDAQ Listing, Effectiveness of Reverse Stock Split

GlobalWise (GWIV) to Hold Inaugural Partner Advisory Board Meeting

COLUMBUS, OH — (Marketwire) — 05/30/12 — GlobalWise Investments, Inc. (OTCBB: GWIV) (OTCQB: GWIV) (www.GlobalWiseInvestments.com) and its wholly owned subsidiary Intellinetics, Inc., a leading-edge technology company focused on the design, implementation and management of cloud-based Enterprise Content Management (“ECM”) systems in both the public and private sectors, today announces an inaugural Partner Advisory Board meeting is taking place in Columbus, Ohio, from May 29 – May 31.

The Partner Advisory Meeting was established by GlobalWise CEO William J. “BJ” Santiago in order to bring together the various forms of sales distribution into a single location to share best practices for selling ECM software services, as well as to jointly develop future applications and improvements to the software portfolio. With ECM software applications being needed for every industry, and any size business, the concern for channel conflict or sharing of trade secrets between competitors is minimal and actually encouraged for the benefit of all those involved.

“I am excited to be hosting the inaugural Partner Advisory Meeting,” stated William J. “BJ” Santiago, CEO of GlobalWise. “Many of our key, strategic Channel Resellers are in attendance for a fantastic event that will be held over a three day period. I see this as an excellent educational forum for our selling partners to get together and learn how each other uses and actively sells our software portfolio. Equally important, our software developers are hearing directly from sales channel partners what the market is asking for so that we are always on the cutting-edge of technology, similar to our migration from premise-based software to an Internet cloud based service delivery model.”

Participants at the inaugural meeting include various Channel Partners who actively market ECM solutions directly to business clients. Those Channel Partners include FormFast, ImageSoft, Primary Solutions, MWA Intelligence (MWAi) and many others. These partners cover a wide range of industries throughout the United States, including state and county governments, insurance, healthcare, court systems and educational institutions. With MWAi, the Company has the opportunity to expand beyond North America into the Asian and EMEA markets internationally.

Also attending is Lexmark International, Inc., which has integrated the Intellivue™ ECM software into their multi-function copiers and printers service offering. Lexmark developed the private-labeled DocMP (Document Management Platform) service that delivers Lexmark clients a multi-function copier and printer embedded with the ECM document management functions provided by Intellinetics’ Intellivue™ software. To see how Lexmark has integrated the Intellivue™ ECM technology into the DocMP platform, please click the following link to watch a YouTube video demonstration: http://youtu.be/69mnWMFy7uA.

“Lexmark is a marquee relationship for GlobalWise and Intellinetics,” added Santiago. “By integrating the Intellivue™ software into an industry-leading hardware manufacturer like Lexmark, we instantly expanded our sales opportunities with a low-cost, private-labeled sales distribution model. Similar to our Channel Distribution model, this hardware integration approach is another method to expand our sales scope for our software products with cost-effective customer acquisition strategies. I think all of our sales distribution partners will enjoy the three day event and will leave with exciting new ways to market ECM solutions.”

About GlobalWise Investments, Inc.

GlobalWise Investments, Inc., via its wholly owned subsidiary Intellinetics, Inc., is a Columbus, Ohio based Enterprise Content Management (ECM) pioneer with industry-leading software that delivers cloud ECM based solutions on-demand. The Company’s flagship platform, Intellivue™, represents a new industry benchmark and game-changing solution by enabling clients to access and manage the content of every scanned document, file, spreadsheet, email, photo, audio file or video tape — virtually anything that can be digitized — in their enterprise from any PC, laptop, tablet or smartphone from anywhere in the world.

For additional information, please visit the Company’s corporate website: www.GlobalWiseInvestments.com

This press release may contain “forward-looking statements.” Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot predict the effect that market conditions, customer acceptance of products, regulatory issues, competitive factors, or other business circumstances and factors described in our filings with the Securities and Exchange Commission may have on our results. The company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

GlobalWise Investments, Inc.
Columbus, Ohio
www.GlobalWiseInvestments.com
614-388-8909
Contact@GlobalWiseInvestments.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975

Wednesday, May 30th, 2012 Uncategorized Comments Off on GlobalWise (GWIV) to Hold Inaugural Partner Advisory Board Meeting

CytRx (CYTR) Details INNO-206 Clinical Cancer Research Publication Findings

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that in animal and in vitro studies, its tumor-targeting doxorubicin conjugate INNO-206 showed anti-multiple myeloma effects and enhanced the anti-tumor effects of bortezomib, which is approved for the treatment of relapsed multiple myeloma. The research was published in the May 22, 2012 online issue of peer-reviewed Clinical Cancer Research.

“Anthracyclines including doxorubicin have shown efficacy especially in combination with other therapies for the treatment of multiple myeloma; however, side effects limit their use,” said James R. Berenson, M.D., Medical & Scientific Director at the Institute for Myeloma & Bone Center Research, where the studies were conducted. “We found that, in our mouse models of human myelomas, INNO-206 alone produced marked anti-multiple myeloma effects at a dose at which doxorubicin alone was extremely toxic, and the combination of INNO-206 and bortezomib produced increased anti-multiple myeloma effects compared to either agent alone.”

Dr. Berenson presented earlier research showing that INNO-206 safely and effectively delivered doxorubicin at higher doses than conventional doxorubicin to human myeloma cancers grown in immune-deficient mice. These findings were presented at the December 2010 Annual Meeting and Exposition of the American Society of Hematology (ASH).

CytRx President and CEO Steven A. Kriegsman said, “This study provides further evidence that INNO-206 could have applicability in multiple cancer indications. We are initially conducting clinical trials with INNO-206 in soft tissue sarcoma and more recently in advanced pancreatic ductual adenocarcinomas.”

Complete results from the CytRx Phase 1b/2 clinical trial with INNO-206 in patients principally with soft tissue sarcoma will be presented at the June American Society of Clinical Oncology (ASCO) conference in Chicago, Illinois, on Sunday, June 3. CytRx will host an investor conference call accompanied by a slide presentation on Monday, June 4, at 9:00 a.m. Central time (10:00 a.m. Eastern time) to discuss the complete clinical trial data. To access the conference call, dial 888-463-4383 (U.S. and Canada) or 706-679-5355 (international callers).

The webcast and the slide presentation will be available on the Investor Relations section of the CytRx website simultaneously. A replay of the call and webcast will begin approximately two hours after the live call has ended. To access the replay, dial 855-859-2056 (U.S. and Canada) or 404-537-3406 (international callers) and enter the conference ID number: 77958605.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. With its tumor-targeted doxorubicin conjugate INNO-206, CytRx has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication, and recently initiated a Phase 2 trial for patients with advanced pancreatic ductual adenocarcinomas. CytRx’s pipeline also includes tamibarotene, which it is testing in a double-blind, placebo-controlled, international Phase 2b clinical trial in patients with non-small-cell lung cancer, and which is in a clinical trial as a treatment for acute promyelocytic leukemia (APL). The Company completed its evaluation of bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib. For more information about the Company, visit www.cytrx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks relating to the timing, outcome or results of any future pre-clinical or clinical testing of INNO-206 as a treatment for multiple myeloma, the risk that any future human testing of INNO-206 for multiple myeloma might not produce results similar to those seen in animals, risks or uncertainties related to the outcome, timing and results of CytRx’s clinical trials with INNO-206, including the Phase 1b/2 clinical trial for INNO-206 in patients with advanced solid tumors and the Phase 2b clinical trials for INNO-206 as a treatment for soft tissue sarcomas and pancreatic cancer, uncertainties regarding regulatory approvals for current and future clinical testing, and the scope of the clinical testing that may eventually be required by regulatory authorities, the risk that INNO-206 might not show greater efficacy than doxorubicin notwithstanding the administration of higher doses than the standard of care, uncertainties regarding whether INNO-206 effectively targets doxorubicin to tumors, the significant time and expense that will be incurred in developing any of the potential commercial applications for INNO-206, including for soft tissue sarcomas, risks related to CytRx’s ability to manufacture its drug candidates, including INNO-206, in a timely fashion, cost-effectively or in commercial quantities in compliance with stringent regulatory requirements, risks related to CytRx’s need for additional capital or strategic partnerships to fund its ongoing working capital needs and development efforts, including any future clinical development of INNO-206, and the risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx’s most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Tuesday, May 29th, 2012 Uncategorized Comments Off on CytRx (CYTR) Details INNO-206 Clinical Cancer Research Publication Findings

China Automotive Systems (CAAS) Redeems All Convertible Notes

WUHAN, China, May 29, 2012 /PRNewswire-Asia-FirstCall/ — China Automotive Systems, Inc. (“CAAS” or the “Company”) (NASDAQ: CAAS), a leading power steering components and systems supplier in China, today announced that on May 25, 2012 it redeemed all of its outstanding senior convertible notes. The negotiated total redemption price was US$32.4 million, which includes all principal, accrued and unpaid interest and the make-whole amounts as of the date of redemption.

The five-year senior convertible notes were issued in February 2008 with an original total principal amount of $35 million, a scheduled maturity date of February 15, 2013 and a conversion price per share of $7.0822. In April 2009, the Company redeemed $5 million of the principal amount of the convertible notes. On March 1, 2011, upon the conversion of $6.4 million of the principal amount of the convertible notes, 907,708 common shares were issued at a conversion price of $7.0822 per share. The remaining total principal amount of the senior convertible notes was US$23.6 million. As a result of the redemption of the senior convertible notes, the total share count on a fully diluted basis will be reduced by approximately 3.3 million shares.

As at March 31, 2012, all the components of the senior convertible notes on the Company’s condensed unaudited consolidated balance sheets totaled at $36.7 million, including $23.6 million of convertible notes payable, $4.4 million of compound derivative liabilities, $8.3 million of accrued make-whole redemption interest expense and $0.4 million of accrued and unpaid coupon interest. As of that same date, CAAS reported cash and equivalents of US$79.9 million. For 2011, net cash flow from operating activities was US$34.1 million and capital expenditures approximated US$14.9 million. For the first quarter of 2012, net cash flow from operating activities was US$8.5 million and capital expenditures approximated US$2.0 million.

Mr. Jie Li, chief financial officer, commented, “CAAS used the funds from the senior convertible notes to build its operations and make itself a stronger competitor in the global steering market. The Company has been generating strong cash flows, and decided to redeemed the notes before their maturity date. CAAS will continue to utilize its improved balance sheet and strong free-cash-flow generation to create long-term shareholder value.”

About China Automotive Systems, Inc.

Based in Hubei Province, the People’s Republic of China, China Automotive Systems, Inc. is a leading supplier of power steering components and systems to the Chinese automotive industry, operating through nine Sino-foreign joint ventures. The Company offers a full range of steering system parts for passenger automobiles and commercial vehicles. The Company currently offers four separate series of power steering with an annual production capacity of over 3.5 million sets, steering columns and steering hoses. Its customer base is comprised of leading Chinese auto manufacturers, such as China FAW Group, Corp., Dongfeng Auto Group Co., Ltd., BYD Auto Company Limited, Beiqi Foton Motor Co., Ltd., Chery Automobile Co., Ltd. and Chrysler North America, outside of North America.

Forward Looking Statements

This press release contains statements that are “forward-looking statements” as defined under the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our estimates and assumptions only as of the date of this press release. These forward-looking statements include statements regarding the qualitative and quantitative effects of the accounting errors, the periods involved, the nature of the Company’s review and any anticipated conclusions of the Company or its management and other statements that are not historical facts. Our actual results may differ materially from the results described in or anticipated by our forward-looking statements due to certain risks and uncertainties. As a result, the Company’s actual results could differ materially from those contained in these forward-looking statements due to a number of factors, including those described under the heading “Risk Factors” in the Company’s Form 10-K annual report filed with the Securities and Exchange Commission on March 9, 2012, and in documents subsequently filed by the Company from time to time with the Securities and Exchange Commission. We expressly disclaim any duty to provide updates to any forward-looking statements made in this press release, whether as a result of new information, future events or otherwise.

For more information, please visit: http://www.caasauto.com or contact:

Jie Li
Chief Financial Officer
China Automotive Systems, Inc.
Email: jieli@chl.com.cn

Kevin Theiss
Investor Relations
Grayling
Tel:   +1-646-284-9409
Email: kevin.theiss@grayling.com

SOURCE China Automotive Systems, Inc.

Tuesday, May 29th, 2012 Uncategorized Comments Off on China Automotive Systems (CAAS) Redeems All Convertible Notes

China HGS (HGSH) Appoints Samuel Shen as Chief Financial Officer

Samuel Shen has been a Vice President of Finance for the Company since November 2011. From September 2011 to his appointment, Mr. Shen was Managing Director at Bluehill Investment Advisory Group, a North American and People’s Republic of China based consulting firm, where he helped several U.S.- and Canadian-listed Chinese companies with financial reporting, internal control implementation, and SOX compliance training. From 2006 to 2011, Mr. Shen was an Audit Assurance Manager at MSCM LLP in Toronto, where he managed audit engagements for U.S. and Canadian public companies in real estate, health care, manufacturing, and IT industries. Mr. Shen is fluent in English and Chinese.

Mr. Shen holds a Master of Management and Accounting from the Rotman School of Management, University of Toronto. He has reporting experience under IFRS, U.S. and Canadian GAAP and holds both Chartered Accountant Canada and Certified Public Accountant designations.

“I am very pleased that Samuel accepts the appointment as the Chief Financial Officer and joins our management team. As a young public company in the U.S. capital market, we are in need of talent such as Samuel. We believe that Samuel’s previous experience working with established U.S.-listed Chinese companies will help the Company in further strengthening our corporate governance and internal controls,” said Mr. Xiaojun Zhu, Chairman and Chief Executive Officer of China HGS. “We also expect Samuel to be an effective liaison between the Company and our shareholders and help our investors to gain a better understanding of the Company. We believe that Samuel will be a valuable addition to our leadership team as we execute our business strategies and create value for shareholders.”

About China HGS Real Estate Inc:

China HGS Real Estate Inc., through its wholly owned subsidiary, Shaanxi Guangsha Investment and Development Group Co., Ltd., has specialized since 1995 in real estate development in China’s third-tier and fourth-tier cities. The Company’s real estate properties include multi-layer, sub-high-rise, and high-rise apartment buildings. The Company possesses the national Grade-I real estate qualification and was ranked as the No. 1 property developer in Hanzhong, Shaanxi Province in terms of market share in 2007, 2008, 2009, 2010, and 2011.

Forward-looking Statements:

This press release contains certain statements that may include ‘forward-looking statements’. All statements other than statements of historical fact included herein are ‘forward-looking statements’. These forward looking statements are often identified by the use of forward-looking terminology such as ‘believes,’ ‘expects’ or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website http://www.sec.gov. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Contact:

Company Contact:
Mr. Randy Xiong, Deputy GM
E-mail: xr968@163.net
Tel:  +86 (91) 6262 2612

Investor Relations Contact:
Jon Cunningham
RedChip Companies, Inc.
1-800-733-2447, Ext. 107
info@redchip.com
http://www.redchip.com

SOURCE China HGS Real Estate Inc.

Tuesday, May 29th, 2012 Uncategorized Comments Off on China HGS (HGSH) Appoints Samuel Shen as Chief Financial Officer

LodgeNet (LNET) Integrates Broadband and Media Sales Teams to Better Serve Hospitality Customers

Single Point-of-Contact Sales Approach Designed to Drive Growth of Business Operational Streamlining Expands Support for Four Screen Services Strategy

SIOUX FALLS, S.D., May 29, 2012 /PRNewswire/ — LodgeNet Interactive Corporation (NASDAQ: LNET), the leading provider of interactive media and connectivity services to hospitality and healthcare businesses and the consumers they serve, announced today that they have integrated their Broadband and Media product and sales teams into a unified organization that will market the company’s full suite of services through a single face and voice to its customers.

(Logo:  http://photos.prnewswire.com/prnh/20080115/AQTU120LOGO)

The re-aligned, cross-functional team will offer LodgeNet customers a single point of contact for Media and Broadband services, including bundled “four screen” solutions that can help hoteliers reach guests through not only the interactive television (iTV) but the laptops, smartphones and tablet devices that people are traveling with today.

“We can now expand upon the deep relationships from our media business and further increase our value to customers by offering not only iTV and mobile services but also the IP-based broadband services that are integral to a successful four screen strategy,” said Scott C. Petersen, President & CEO for LodgeNet. “In the DOCOMO Freedom solution we have a best-in-class broadband service that supports all of the most commonly used mobile devices and offers hoteliers unprecedented reporting, bandwidth management and pricing flexibility. Consolidating our sales team will allow us to more effectively bring those features to hoteliers in combination with our Media offerings. We look forward to developing new apps and products that will help our customers improve their economics and guest relationships through both our Envision™ iTV and Broadband platforms.”

Petersen added that non-sales Broadband activities will continue to be maintained in the company’s Atlanta office, which houses the division’s dedicated technical and customer support functions including an employee-based 24×7 helpdesk for hotel staff and guests.

“I am enthused at what this means for our customers, who will benefit from a more expedited sales process and enhanced responsiveness as the result of this re-alignment,” added David Goldstone, Vice President Sales & Hotel Relations for LodgeNet, who will oversee the integrated team. “Our sales personnel bring a tremendous amount of knowledge and experience in both the media and broadband spaces, and we look forward to putting that expertise to work for hoteliers who are currently our customers as well as those we will have the privilege of serving in the future.”

About LodgeNet

LodgeNet Interactive Corporation is the leading provider of interactive media and connectivity services to hospitality and healthcare businesses and the consumers they serve. Recently named by Advertising Age as one of the Leading 100 US Media Companies, LodgeNet Interactive serves approximately 1.6 million hotel rooms worldwide in addition to healthcare facilities throughout the United States. The Company’s services include: Interactive Television, Broadband and Advertising Media Solutions along with nationwide technical and professional support services. LodgeNet Interactive Corporation owns and operates businesses under the industry leading brands: LodgeNet, The Hotel Networks and LodgeNet Healthcare. LodgeNet Interactive is listed on NASDAQ and trades under the symbol LNET. For more information, please visit www.lodgenet.com.

LodgeNet, the LodgeNet logo, and Envision are trademarks or registered trademarks of LodgeNet Interactive Corporation. All other trademarks are the property of their respective owners.

SOURCE LodgeNet Interactive Corporation

Tuesday, May 29th, 2012 Uncategorized Comments Off on LodgeNet (LNET) Integrates Broadband and Media Sales Teams to Better Serve Hospitality Customers

IsoRay’s (ISR) Cesium-131 Prostate Cancer Treatment Featured on Discovery Channel

RICHLAND, WA — (Marketwire) — 05/29/12 — IsoRay Inc. (NYSE Amex: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced that Discovery Channel has featured the Company’s Cesium-131 brachytherapy (internal radiation therapy) treatment for localized prostate cancer.

Discovery Channel Chief Medical Expert John Whyte, MD, MPH, spoke with UPMC urologist Dr. Ronald Benoit about the advantages of using Cesium-131 over traditional isotopes. Dr. Benoit explained that UPMC has been using Cesium-131 over a six year period. UPMC’s study found that its patients benefited from the minimally invasive treatment that resulted in reduced urinary problems. Typically, urinary problems last up to 18 months after treatment with other brachytherapy options. When using Cesium-131, Dr. Benoit explained, urinary symptoms were gone in 3 to 6 months. View the Discovery Channel story here.

One in six men will be diagnosed with prostate cancer during their lifetimes. It is the second leading cause of cancer deaths among American men, claiming some 30,000 lives annually. About 1 man in 36 will die of prostate cancer, according to the American Cancer Society, which reports that about 241,740 new cases of prostate cancer will be diagnosed in 2012. Only lung cancer claims the lives of more men each year.

IsoRay is the exclusive manufacturer of Cesium-131. The ground-breaking brachytherapy treatment represents one of the most important advancements in internal radiation therapy in 20 years. Cesium-131 allows for the internal radiation treatment of many different cancers because of its incomparable combination of high energy (its unique tissue penetrating capability reaching just far enough to treat the cancer) and its 9.7 day half-life (its unrivaled speed in giving off therapeutic radiation). The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and mesh, and several new implantable devices.

IsoRay Chairman and CEO Dwight Babcock commented, “Cesium-131’s success in treating low and intermediate risk prostate cancer is just the beginning. IsoRay has built the foundation for the use of Cesium-131 in the successful treatment of cancers throughout the body. We expect more physicians and institutions in the medical community to adopt the use of Cesium-131 for the treatment of multiple cancers as they become aware of its dramatic impact on survivability and quality of life benefits for their patients.”

In addition to its CMS codes, Cesium-131 is FDA-cleared in seed form for the treatment of prostate cancer, lung cancer, ocular melanoma cancer, brain cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body.

About IsoRay, Inc.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the exclusive producer of Cesium-131 internal radiation therapy, which is expanding brachytherapy options throughout the body and the GliaSite® radiation therapy system, the world’s only balloon catheter device used in the treatment of brain cancer. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 and the GliaSite® radiation therapy system by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.

Safe Harbor Statement
Statements in this news release about IsoRay’s future expectations, including: the advantages of Cesium-131 seed, whether outcomes, including lessened side effects, from this study will be experienced by other users of our products, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether IsoRay’s Cesium-131 seed and other delivery methods for Cesium-131 will be used to successfully treat additional cancers and malignant disease, whether additional physicians and institutions will adopt the use of Cesium-131 to treat other cancers will be successful, and all other statements in this release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of early clinical studies, whether this and other studies with Cesium-131 result in favorable patient outcomes, patient results achieved when Cesium-131 is used for the treatment of cancers and malignant diseases beyond prostate cancer, successful completion of future research and development activities, and other risks detailed from time to time in IsoRay’s reports filed with the SEC.

Contact:
Sharon Schultz
(301) 351-0109

Tuesday, May 29th, 2012 Uncategorized Comments Off on IsoRay’s (ISR) Cesium-131 Prostate Cancer Treatment Featured on Discovery Channel

BancTrust Financial (BTFG) and Trustmark Corp. Announce Definitive Merger Agreement

Trustmark Corporation (NASDAQ:TRMK) (“Trustmark”) and BancTrust Financial Group, Inc. (NASDAQ:BTFG) (“BancTrust”) announced today the signing of a definitive agreement pursuant to which BancTrust will merge into Trustmark. BancTrust has 49 offices throughout Alabama and the Florida Panhandle with $1.3 billion in loans and $1.8 billion in deposits as of March 31, 2012.

Under the terms of the definitive agreement, which has been approved unanimously by the Boards of Directors of both companies, holders of BancTrust common stock will receive 0.125 shares of Trustmark common stock for each share of BancTrust common stock in a tax-free exchange. Trustmark will issue approximately 2,245,923 shares of its common stock for all issued and outstanding shares of BancTrust common stock. Based upon a price of $24.66 per share of Trustmark common stock, the transaction is valued at approximately $55.4 million, or $3.08 per share of BancTrust common stock. Trustmark intends to repurchase the $50.0 million of BancTrust preferred stock and associated warrant issued to the U. S. Department of Treasury under the Capital Purchase Program.

Daniel A. Grafton, Chairman of Trustmark, said, “BancTrust is a respected financial institution with long-standing customer relationships. This transaction provides an excellent opportunity for Trustmark to enhance its franchise by expanding into attractive Alabama markets, including Mobile and Montgomery, as well as increase scale in our existing Florida Panhandle markets.”

Gerard R. Host, President and Chief Executive Officer of Trustmark, commented, “This is a strategic opportunity that will be meaningfully accretive to Trustmark’s earnings per share in 2013 and beyond. We have completed extensive due diligence, including multiple reviews of BancTrust’s loan portfolio and significant real estate collateral. We understand the inherent credit risk of the portfolio, and we have a proven record of managing real estate related assets in a challenging economic environment. Trustmark’s pro forma capital will continue to significantly exceed ‘well-capitalized’ levels, providing capacity for loan growth in an improving economy.”

W. Bibb Lamar, Jr., President and Chief Executive Officer of BancTrust, stated, “We are delighted to become a part of the Trustmark organization and believe that the combination created by our two companies will enable us to better serve our customers through a broader array of products and services. Trustmark’s reputation, financial strength and capabilities will enhance our ability to meet the expanding needs of our customers. Our shareholders will be receiving shares of a very strong, successful banking company.”

The transaction is expected to close during the fourth quarter of 2012 and is subject to approval by regulatory authorities and BancTrust’s shareholders, as well as certain other customary closing conditions.

Trustmark was advised by the investment banking firm Sandler O’Neill + Partners, L.P., as well as the law firm Wachtell, Lipton, Rosen & Katz. BancTrust was advised by the investment banking firm Keefe, Bruyette & Woods, Inc., and the law firms Hand Arendall and DLA Piper LLP (US).

ADDITIONAL INFORMATION

Additional information regarding this transaction is available on the investor relations section of Trustmark’s website at www.trustmark.com. Trustmark and BancTrust executives will conduct a conference call with analysts on Tuesday, May 29, 2012, at 9:00 a.m. Central Time to discuss this announcement. Interested parties may listen to the conference call by dialing (877) 883-0383, pass code 1701266 or by clicking on the link provided under the Investor Relations section of Trustmark’s website at www.trustmark.com. A replay of the conference call will also be available through June 14, 2012 in archived format at the same web address or by calling (877) 344-7529, pass code 10014734. Additional material information regarding this announcement is also available in a presentation on the investor relations section of Trustmark’s website at www.trustmark.com.

Trustmark is a financial services company providing banking and financial solutions through over 170 offices in Florida, Mississippi, Tennessee and Texas.

BancTrust Financial Group, Inc. is a registered bank holding company headquartered in Mobile, Alabama, and provides an array of traditional financial services through 40 bank offices in the southern two thirds of Alabama and nine bank offices in northwest Florida.

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the proposed merger between Trustmark and BancTrust, Trustmark will file with the Securities and Exchange Commission (the “SEC”) a Registration Statement on Form S-4 that will include a proxy statement of BancTrust and a prospectus of Trustmark. BancTrust shareholders are urged to read the proxy statement/prospectus regarding the proposed transaction when it becomes available, as well as other documents filed with the SEC, because they will contain important information. You will be able to obtain a copy of the proxy statement/prospectus, as well as other filings containing information about Trustmark and BancTrust, without charge, at the SEC’s website (www.sec.gov). You may also obtain copies of all documents filed with the SEC, without charge, by directing a request to F. Joseph Rein, Jr., Trustmark Corporation, 248 East Capitol Street, Suite 310, Jackson, Mississippi 39201, telephone 601-208-6898 or F. Michael Johnson, BancTrust Financial Group, Inc., 107 St. Francis Street, P.O. Box 3067, Mobile, Alabama 36602, telephone 251-431-7813.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by words such as “may,” “hope,” “will,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential,” “continue,” “could,” “future” or the negative of those terms or other words of similar meaning. You should read statements that contain these words carefully because they discuss our future expectations or state other “forward-looking” information. These forward-looking statements involve a number of risks and uncertainties. Trustmark and BancTrust caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement. Such forward-looking statements include, but are not limited to, statements about the benefits of the proposed merger involving Trustmark and BancTrust, Trustmark’s and BancTrust’s plans, objectives, expectations and intentions, the expected timing of completion of the transaction, and other statements that are not historical facts. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in Trustmark’s and BancTrust’s filings with the SEC. These include risks and uncertainties relating to: the ability to obtain the requisite BancTrust shareholder approval; the risk that Trustmark or BancTrust may be unable to obtain governmental and regulatory approvals required for the merger, or required governmental and regulatory approvals may delay the merger or result in the imposition of conditions that could cause the parties to abandon the merger; the risk that a condition to closing of the merger may not be satisfied; the timing to consummate the proposed merger; the risk that the businesses will not be integrated successfully; the risk that the cost savings and any other synergies from the transaction may not be fully realized or may take longer to realize than expected; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; the diversion of management time on merger-related issues; general worldwide economic conditions and related uncertainties; the effect of changes in governmental regulations; and other factors discussed or referred to in the “Risk Factors” section of each of Trustmark’s and BancTrust’s most recent Annual Report on Form 10-K filed with the SEC. Each forward-looking statement speaks only as of the date of the particular statement and neither Trustmark nor BancTrust undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

PARTICIPANTS IN THE MERGER SOLICITATION

Trustmark, BancTrust and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from BancTrust shareholders in connection with the proposed transaction. Information about Trustmark’s directors and executive officers is set forth in its proxy statement for its 2012 Annual Meeting of Stockholders, which was filed with the SEC on March 30, 2012, and its Annual Report on Form 10-K for the year ended December 31, 2011, filed on February 27, 2012. These documents are available free of charge at the SEC’s website at www.sec.gov, or by going to Trustmark’s Investor Relations page on its corporate website at www.trustmark.com. Information about BancTrust’s directors and executive officers is set forth in its proxy statement for its 2011 Annual Meeting of Stockholders, which was filed with the SEC on April 12, 2011, and its Annual Report on Form 10-K for the year ended December 31, 2011, filed on April 12, 2012, as amended on April 27, 2012. These documents are available free of charge at the SEC’s website at www.sec.gov, or by going to BancTrust’s Investor Relations page on its corporate website at www.banktrustonline.com. Additional information regarding the interests of participants in the solicitation of proxies in connection with the transaction will be included in the proxy statement/prospectus that Trustmark intends to file with the SEC.

Tuesday, May 29th, 2012 Uncategorized Comments Off on BancTrust Financial (BTFG) and Trustmark Corp. Announce Definitive Merger Agreement

Infrastructure Developments Corp. (IDVC) Issues Corporate and Shareholder Update

SALT LAKE CITY, May 29, 2012 (GLOBE NEWSWIRE) — Infrastructure Developments Corp. (OTCBB:IDVC) (the “Company”) wishes to clarify certain considerations regarding the public market for its common stock and recent business development activities.

Over the past fifteen months the Company borrowed $214,000 from an investment firm to finance the startup of its U.S. Navy “Lido” project in Indonesia as well as for general corporate expenses. The Company borrowed the funds on terms that included a conversion option at a discount to the trading price in the market. The subsequent conversion of the debt to stock, and the apparent liquidation of stock in the market, resulted in a significant increase in IDVC’s public float which increase may have resulted in the drop in IDVC’s stock price over the past ten months.

Except for $2,000, all convertible debt that is currently entitled to conversion has been converted to stock as of today’s date. The Company plans to repay the remaining balance of $39,000 that will become convertible beginning in September 2012 prior to any such conversion.

The Company’s losses from the Lido project – due to disputes with local subcontractors and the subsequent termination of the project – resulted in its inability to repay the previous convertible debt. As detailed in the Company’s quarterly and annual reports, its Asian region U.S. military contracting operations division has been suspended due to low margins, heavy competition, and lack of funding to advance start up cash for larger projects.

As also reported in the Company s annual and quarterly reports, it has written off all losses from its quarry operation in the United Arab Emirates, converted nearly all outstanding debt to equity, and has now stabilized its financial situation. The Company is in position now to grow it new businesses with a clean balance sheet and reduced operating losses.

“Due to the previous economic downturn, increased competition in our target markets, and military funding reorganization, we were not as successful in procuring government contracts in the past year,” stated the Company’s ‘s CEO Thomas R. Morgan. “However, with the diversification of our business model into the clean energy arena, coupled with the realignment of strategy as it applies to military activities and other Southeast Asian operations, I am hopeful that we will regain our corporate foothold. I look forward to a much improved outlook for the second half of the current fiscal year.”

The Company continues to evaluate the potential acquisition of InterMedia Development Corporation, a media production company and defense contractor based in Fairfax, Virginia. The Company is awaiting audited financial statements from InterMedia as required to proceed with a merger.

The Company is also in the process of formalizing its relationship with Cleanfield Energy, Inc., with a proposed acquisition plan being currently negotiated and expected to close within the week. Cleanfield is properly set up for compressed natural gas conversions in the Southwest U.S., and is currently bidding on fleet conversions.

Lastly, the Company has been selectively bidding to manage private projects in the booming Thailand construction market, and believes that it will be successful in winning projects that have clear profit margins and no advance funding requirements.

Forward-Looking Statements:

A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties including the acquisition of InterMedia and Cleanfield as subsidiaries, the Company’s ability to procure design and management projects, competitive market conditions, and its s prospects for securing additional sources of financing as required. The actual results that the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties. The Company encourages the public to read the information provided here in conjunction with its most recent filings on Form 10-Q and Form 10-K. The Company’s public filings may be viewed at www.sec.gov.

CONTACT: Infrastructure Developments Corp.
         Thomas Morgan, CEO
         801.488.2006
         trmorgan@idvc.us
         www.idvc.us
Tuesday, May 29th, 2012 Uncategorized Comments Off on Infrastructure Developments Corp. (IDVC) Issues Corporate and Shareholder Update

Daulton Capital Corp. (DUCP) to Acquire 6-18M Ounce Resource in Queensland, Australia

NEW YORK, May 29, 2012 /PRNewswire/ — Daulton Capital Corp. (OTCBB: DUCP), a gold and precious metals exploration company, is pleased to announce that is has entered into an agreement to acquire Grimsby Investments Limited and its subsidiaries including two Australian Companies engaged in a Gold mining project known as the ARX Springs Gold project, located in the Wide Bay Burnett Region of Queensland, Australia.

The agreement provides for the company to acquire Grimsby Investments Limited from its shareholders together with its Singapore company ARX Springs Pte Ltd and the two Australian subsidiaries that hold the gold project known as ARX Springs in exchange for $4,298 billion in consideration, to be satisfied by the issue of 4.148 billion in restricted common stock, $75 million in non-convertible preferred share series with 5 votes per share and $75 million in a ten year non-convertible promissory note issued in favor of shareholders of Grimsby Investments Limited.

The ARX Springs Gold property is located at Coonambula near Eidsvold in Queensland, Australia, and has gold resources estimated at between 16,000,000 to 18,000,000 (Sixteen to Eighteen Million) ounces of gold and estimated to generated a cash flow of $22 billion over the planned 20 year life of the mine based on current gold prices. Queensland, Australia is well known to be a prolific gold producing State since the 1867 Australian gold rush, several major gold producing companies including BHP, Glencore Xstrata, Rio Tinto, Barrick Gold and Anglo American have been active in the State of Queensland and the area where the ARX Springs gold project is located has an extensive history of gold finds going back to early 1888 in the nearby St Johns Creek gold fields.

A spokesperson for Daulton Capital commented, “We are looking forward to working on getting the additional financing required to get the ARX Springs Gold project into gold production in order to maximize shareholder value and we are in talks with leading fund managers worldwide and we hope in next few months we will be able to raise the required capital needed.” Gold continues to be of paramount importance on the global financial markets and the gold prices have been steadily rising over the past several years making our purchase potentially very valuable and rewarding for our shareholders.

The company announced the resignation of Terry Fields and the appointment of Arun Pudur as the President of the company. Arun Pudur is the founder of Celframe, a Multi-Billion Dollar Global technology company with offices in US, India & Malaysia. Arun Ramachandran and Brian James Smith would constitute the new Board of Daulton Capital Corp along with Arun Pudur.

Renowned Business Man Mr. Arun Pudur is the CEO of Celframe Technology Group of Companies since March 2001. Arun Pudur is a widely accomplished and established entrepreneur and investor in the precious minerals and mining industry in Australia, South Africa and other parts of the world. He is a graduate of the University of Bangalore majoring in Business Management.

Mr. Brian James Smith is the Managing Director of BRI Microfine Pty Ltd., a gold recovery technology company since 2008. He has a strong history within the precious mining industry through BRI Microfine Pty Ltd, particularly in Australia. His expertise is focused on development implementation, funding, improvement and expansion of the mining technology and production. BRI has licensed its propriety technology for processing gold ore at Arx Springs gold project.

Mr. Arun Ramachandran is the Co-Founder and Director of renowned advisory firm in Singapore and has over 15 years of experience in corporate finance, accounting, and taxation with very strong knowledge of various business verticals. He is a certified Chartered accountant and has done his MBA from SP Jain Institute of Management, Mumbai majoring in Finance.

The Company further announces that it has decided not to pursue the purchase and exploration of certain previously announced properties located in Papua New Guinea and that the agreements have been mutually terminated.

About Daulton Capital Corporation:

DAULTON CAPITAL CORP. (OTCBB: DUCP) is a natural resource company focused on precious metals. The New Management’s corporate philosophy is to be a Share Holder Value creator, with the objective of exploring, acquiring and operating Gold projects in Australia and other countries to generate real value beginning with ARX Springs Gold Project in Queensland, Australia.

Daulton Capital has formed an experienced management team with the ability to take advantage of the tremendous opportunities that are available in the natural resource sector today. Our focus will be to explore, acquire and develop gold resource projects, and continue to invest in expansion of exploration activities and seek opportunistic special situations that can add to our portfolio of assets within the resource sector.

Please visit www.daultoncapital.com  for more information.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company’s current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please contact
Daulton Capital Corp.
Investor Relations

Email: dcc@celframe.com

Web:  www.daultoncapital.com

Nasdaq: http://www.nasdaq.com/symbol/ducp

Bloomberg: http://www.bloomberg.com/quote/DUCP:US

SOURCE Daulton Capital Corp.

Tuesday, May 29th, 2012 Uncategorized Comments Off on Daulton Capital Corp. (DUCP) to Acquire 6-18M Ounce Resource in Queensland, Australia

MissionIR Features SEFE (SEFE) in Exclusive Interview Featuring CEO Don Johnston

ATLANTA, GA — (Marketwire) — 05/29/12 — MissionIR today announces that its interview with Don Johnston, the Chief Executive Officer of SEFE, Inc. (OTCBB: SEFE), is now available online. The complete interview can be heard at http://sefe.missionir.com/sefe/interview.html.

Mr. Johnston provided a brief overview of the company and its targeted markets, individuals comprising the management team, the key advantages of its Harmony III atmospheric energy system, expansion of its intellectual property portfolio, and future plans to acquire other companies in the green space or form joint ventures.

“It has been a busy year for us,” Mr. Johnston stated in the interview. “We have recently moved our research laboratory in Boulder, Colorado, to a larger facility adjacent to the University of Colorado. As mentioned earlier, the university is a leader in the exploration of atmospheric phenomena. We believe entry into a partnership may accelerate the development of our Harmony projects and provide access to significant resources we will require for the ongoing testing of our products.”

About SEFE, Inc.

SEFE focuses on pushing the boundaries of what’s possible, embracing innovation and employing the cutting-edge to solve problems, and offering sustainable solutions to a world hungry for invention, direction and leadership. SEFE is technology- and solutions-driven, focusing on developing inventions that provide a real-world impact and true profitability. So, success is measured by both a sustainable return on investment, as well as a project’s sustainability from an environmental perspective.

For more information, visit www.SEFElectric.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://www.MissionIR.com

To connect with MissionIR via Facebook, please visit http://www.Facebook.com/MissionIR

To connect with MissionIR via Twitter, please visit http://www.Twitter.com/MissionIR

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company’s actual results to differ materially from those indicated in any forward-looking statements.

Contacts:
SEFE, Inc.
Justin Ackerman
714-495-1927
ir@sefelectric.com

Mission Investor Relations
Atlanta, Georgia
www.MissionIR.com
404-941-8975

Tuesday, May 29th, 2012 Uncategorized Comments Off on MissionIR Features SEFE (SEFE) in Exclusive Interview Featuring CEO Don Johnston